Drug Delivery最新文献_第4页

Constructed transferrin receptor-targeted liposome for the delivery of fluvoxamine to improve prognosis in a traumatic brain injury mouse model. 构建转铁蛋白受体靶向脂质体用于输送氟伏沙明以改善创伤性脑损伤小鼠模型的预后。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-04-15 DOI: 10.1080/10717544.2025.2486840

Liang Mi, Jiangyuan Yuan, Yuxing Jiang, Yuqian Hu, Chuanxiang Lv, Yongqiang Xu, Mingqi Liu, Tao Liu, Xuanhui Liu, Jinhao Huang, Rongcai Jiang, Wei Quan

{"title":"Constructed transferrin receptor-targeted liposome for the delivery of fluvoxamine to improve prognosis in a traumatic brain injury mouse model.","authors":"Liang Mi, Jiangyuan Yuan, Yuxing Jiang, Yuqian Hu, Chuanxiang Lv, Yongqiang Xu, Mingqi Liu, Tao Liu, Xuanhui Liu, Jinhao Huang, Rongcai Jiang, Wei Quan","doi":"10.1080/10717544.2025.2486840","DOIUrl":"https://doi.org/10.1080/10717544.2025.2486840","url":null,"abstract":"The dysregulation of blood-brain barrier (BBB) activates pathological mechanisms such as neuroinflammation after traumatic brain injury (TBI), and glymphatic system dysfunction accelerates toxic waste accumulation after TBI. It is essential to find an effective way to inhibit inflammation and repair BBB and glymphatic system after TBI; however, effective and lasting drug therapy remains challenging because BBB severely prevents drugs from being delivered to central nervous system. Transferrin receptors (TfRs) are mainly expressed on brain capillary endothelial cells. Here, we report a TfR-targeted nanomedicine for TBI treatment by penetrating BBB and delivering fluvoxamine (Flv). The TfR-targeted polypeptide liposome loaded with Flv (TPL-Flv) implements cell targeting ability on human umbilical vein endothelial cells (HUVECs) in vitro detected by flow cytometry, and drug safety was proved through cell viability analysis and blood routine and biochemistry analysis. Afterwards, we established a controlled cortical impact model to explore TPL-Flv administration effects on TBI mice. We confirmed that TPL-Flv could stimulate CXCR4/SDF-1 signaling pathway, activate Treg cells, and inhibit inflammation after TBI. TPL-Flv treatment also alleviated BBB disruption and restored aquaporin-4 (AQP4) polarization, as well as reversed glymphatic dysfunction. Furthermore, TPL-Flv accomplished remarkable improvement of motor and cognitive functions. These findings demonstrate that TPL-Flv can effectively cross BBB and achieve drug delivery to cerebral tissue, validating its potential to improve therapeutic outcomes for TBI.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2486840"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12001850/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143977814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform. 抗原肽递送到抗原呈递细胞使用cd40线圈亲和为基础的平台。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-05-26 DOI: 10.1080/10717544.2025.2486340

Barnabas Nyesiga, Karin Hägerbrand, Laura Varas, Anette Gjörloff Wingren, Mats Ohlin, Peter Ellmark, Laura von Schantz

{"title":"Antigenic peptide delivery to antigen-presenting cells using a CD40-coiled coil affinity-based platform.","authors":"Barnabas Nyesiga, Karin Hägerbrand, Laura Varas, Anette Gjörloff Wingren, Mats Ohlin, Peter Ellmark, Laura von Schantz","doi":"10.1080/10717544.2025.2486340","DOIUrl":"10.1080/10717544.2025.2486340","url":null,"abstract":"Delivery of antigenic peptides to antigen presenting cells (APCs) such as dendritic cells (DCs) using monoclonal antibodies (mAbs) is an attractive approach to evoke antigen-specific T cell activation and improve drug efficacy. Peptide linkage to mAbs has previously been achieved through genetic fusion, chemical conjugation, nano-engineered platforms and high affinity peptides. In this study, we have developed a flexible antibody-peptide linking technology using oppositely charged coiled coil domains to non-covalently link peptides to mAbs. The technology comprises (1) an anti-CD40 mAb connected with negatively charged E domains and (2) an immunogenic OVA peptide (SIINFEKL) from ovalbumin used as a model antigenic peptide fused with positively charged K domains. Combining these constructs leads to the formation of complexes that can be targeted to CD40 expressed on cells. Proof of concept antibody constructs connected with E domains generated from transient expressions exhibited good manufacturability, binding, and stability attributes comparable to a control mAb. Also, optimal repeat lengths for coiled-coil oligomerization domains were identified in these studies. Binding kinetics studies showed that connecting E domains to mAbs do not impede Fc gamma and neonatal receptor interactions. Additionally, formation of stable complexes capable of binding CD40 expressing cells was demonstrated in vitro. In vivo functionality evaluations showed that treatment of human CD40 transgenic mice with complexes elicited expansion of OVA peptide-specific CD8+ T cells and potent antitumor effects superior to peptide monotherapies. Overall, these findings demonstrate that the technology has great potential for application as an in vivo tool for antigenic peptide delivery.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2486340"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12107651/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Adipose tissue-targeted drug delivery for treating obesity: current opportunities and challenges. 脂肪组织靶向给药治疗肥胖：当前的机遇和挑战。

IF 8.1 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-08-22 DOI: 10.1080/10717544.2025.2547751

Taimin Luo, Lei Chen, Kun Tu, Longyang Jiang, Sicheng Liang, Shurong Wang, Yilan Huang, Xuping Yang

{"title":"Adipose tissue-targeted drug delivery for treating obesity: current opportunities and challenges.","authors":"Taimin Luo, Lei Chen, Kun Tu, Longyang Jiang, Sicheng Liang, Shurong Wang, Yilan Huang, Xuping Yang","doi":"10.1080/10717544.2025.2547751","DOIUrl":"https://doi.org/10.1080/10717544.2025.2547751","url":null,"abstract":"Obesity has emerged as a global public health crisis in the 21st century, with its prevalence continuing to rise worldwide. Beyond its well-established links to metabolic diseases (diabetes, hypertension, dyslipidemia, and cardiovascular disease), obesity correlates significantly with oncological and musculoskeletal morbidity. Researchers have discovered that converting energy-storing white adipose tissue (WAT) into energy-expending thermogenic fat through external stimuli or browning agents-a process termed 'white fat browning'-has become a novel therapeutic strategy for obesity and its complications. This transformation is mediated by the activation of key factors such as uncoupling protein 1 (UCP1), which promotes thermogenesis and energy expenditure in adipocytes, thereby reducing fat accumulation. Studies have shown that certain pharmacological agents (e.g. β3-adrenergic receptor agonists) or natural compounds (e.g. resveratrol, capsaicin) can effectively induce white fat browning. However, systemic administration of these agents may cause off-target effects, such as cardiovascular overstimulation or metabolic disturbances, significantly limiting their clinical application. To address this challenge, adipose tissue-targeted drug delivery systems have been developed. These systems utilize either the unique microenvironment of adipose tissue (e.g. specific receptor expression) or nanocarrier technologies (e.g. polymeric nanoparticles) to precisely deliver browning agents to target fat depots. This review summarizes recent advances in targeted delivery vectors for obesity treatment via white fat browning, while also discussing challenges in nanomaterial design, targeting strategy optimization, and clinical translation.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2547751"},"PeriodicalIF":8.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12377096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems. 基于蛋白质的纳米颗粒给药系统口服治疗炎症性肠病的进展。

IF 8.1 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-08-11 DOI: 10.1080/10717544.2025.2544689

Zhihao Lin, Ziheng Zhao, Xianrui Lin, Zhenlin Yang, Lin Wang, Rui Xi, Dingpei Long

{"title":"Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems.","authors":"Zhihao Lin, Ziheng Zhao, Xianrui Lin, Zhenlin Yang, Lin Wang, Rui Xi, Dingpei Long","doi":"10.1080/10717544.2025.2544689","DOIUrl":"10.1080/10717544.2025.2544689","url":null,"abstract":"Inflammatory bowel disease (IBD) comprises chronic autoimmune disorders with significant morbidity, highlighting the need for advanced, noninvasive, targeted therapies. Protein-based nanoparticle drug delivery systems (PNP-DDSs) have emerged as promising platforms to overcome limitations of conventional IBD therapies by improving drug stability and bioavailability while enabling colon-specific delivery. This review systematically classifies PNP-DDSs derived from natural proteins (albumin, gelatin, silk fibroin, and plant-derived proteins) and discusses their design principles along with strategies for intestinal targeting, including particle size and surface charge modulation, stimuli-responsive release (triggered by pH, reactive oxygen species, or enzymes), and active targeting. It highlights recent preclinical advances with oral PNP-DDSs delivering curcumin, resveratrol, 5-aminosalicylic acid, quercetin, and other anti-inflammatory agents, which demonstrate the therapeutic potential of these nanoplatforms in IBD models. Despite promising preclinical outcomes, clinical translation of PNP-DDSs remains challenging due to patient heterogeneity, manufacturing scale-up difficulties, and safety concerns. Future progress will require interdisciplinary innovation and optimization of multi‑stimuli-responsive designs for precise and safe clinical application of PNP-DDSs in IBD management.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2544689"},"PeriodicalIF":8.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12344685/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144820896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Machine learning-assisted design of immunomodulatory lipid nanoparticles for delivery of mRNA to repolarize hyperactivated microglia. 机器学习辅助设计免疫调节脂质纳米颗粒，用于递送mRNA以使过度激活的小胶质细胞再极化。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-03-03 DOI: 10.1080/10717544.2025.2465909

Mehrnoosh Rafiei, Akbar Shojaei, Ying Chau

{"title":"Machine learning-assisted design of immunomodulatory lipid nanoparticles for delivery of mRNA to repolarize hyperactivated microglia.","authors":"Mehrnoosh Rafiei, Akbar Shojaei, Ying Chau","doi":"10.1080/10717544.2025.2465909","DOIUrl":"10.1080/10717544.2025.2465909","url":null,"abstract":"Regulating inflammatory microglia presents a promising strategy for treating neurodegenerative and autoimmune disorders, yet effective therapeutic agents delivery to these cells remains a challenge. This study investigates modified lipid nanoparticles (LNP) for mRNA delivery to hyperactivated microglia, particularly those with pro-inflammatory characteristics, utilizing supervised machine learning (ML) classifiers. We developed and screened a library of 216 LNP formulations with varying lipid compositions, N/P ratios, and hyaluronic acid (HA) modifications. The transfection efficiency of eGFP mRNA was assessed in the BV-2 murine microglia cell line under different immunological states, including resting and activated conditions (LPS-activated and IL4/IL13-activated). ML-guided morphometric analysis tracked the phenotypes of various microglia subtypes before and after transfection. Four supervised ML classifiers were investigated to predict transfection efficiency and phenotypic changes based on LNP design parameters. The Multi-Layer Perceptron (MLP) neural network emerged as the best-performing model, achieving weighted F1-scores ≥0.8. While it accurately predicted responses from LPS-activated and resting cells, it struggled with IL4/IL13-activated cells. The MLP model was validated by predicting the performance of four unseen LNP formulations delivering eGFP mRNA to LPS-activated BV2 cells. HA-LNP2 emerged as optimal formulation for delivering target IL10 mRNA, effectively suppressing inflammatory phenotypes, evidenced by shifts in cell morphology, increased IL10 expression, and reduced TNF-α levels. We also evaluated HA-LNP2 on LPS-activated human iPSC-derived microglia, confirming its efficacy in modulating inflammatory responses. This study highlights the potential of tailored LNP design and ML techniques to enhance mRNA therapy for neuroinflammatory disorders by leveraging carrier's immunogenic properties to modulate microglial responses.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2465909"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878168/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of a conjunctival contact-type drug delivery device for latanoprost using hyaluronic acid. 利用透明质酸开发拉坦前列腺结膜接触式给药装置。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-02-04 DOI: 10.1080/10717544.2025.2459775

Soomin Lee, Mi-Young Jung, Choul Yong Park

{"title":"Development of a conjunctival contact-type drug delivery device for latanoprost using hyaluronic acid.","authors":"Soomin Lee, Mi-Young Jung, Choul Yong Park","doi":"10.1080/10717544.2025.2459775","DOIUrl":"10.1080/10717544.2025.2459775","url":null,"abstract":"Effective topical drug delivery is crucial for glaucoma treatment, necessitating more convenient methods to enhance patient compliance. This study evaluates the efficacy and safety of using freeze-dried hyaluronic acid (HA) as a carrier for a novel conjunctival-contact drug delivery system. We developed HA tablets loaded with latanoprost (HA-latanoprost) and verified the concentration using high-performance liquid chromatography. Twenty mice (C57BL6) were divided into four groups (n = 5 per group): normal saline (group 1), control HA tablet (group 2), Xalatan™ (group 3), and HA-latanoprost tablet (group 4). Treatments were administered to the right eyes, with the left eyes serving as no-treatment controls. Intraocular pressure (IOP) and irritation (measured by scratching motions) were monitored for 10 days. On day 10, we quantified gene expression of inflammatory cytokines and IOP-affecting proteins using polymerase chain reaction, and performed histological and immunohistochemical analyses. Results showed that IOP was significantly lower in groups 3 and 4 compared to the other groups, with group 4 exhibiting the greatest reduction by day 10. Group 4 also experienced less irritation. Additionally, group 4 had lower expression of inflammatory cytokine genes and higher expression of IOP-lowering protein genes compared to group 3. No significant side effects were observed in any group. Overall, HA-latanoprost effectively lowered IOP and reduced ocular irritation more than latanoprost eyedrops in mice. However, these results are based on animal testing, so further development is needed for clinical use.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2459775"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11795754/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143188641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring the efficacy and constraints of platinum nanoparticles as adjuvant therapy in silicosis management. 探讨纳米铂辅助治疗矽肺的疗效和局限性。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-01-13 DOI: 10.1080/10717544.2024.2445257

Ge Ban, Yuanjie Chen, Yingbing Liang, Xiaona Wang, Dan Ding, Rui Liu, Jingjing Jia, Ran Zhao, Chenxia Wang, Na Li

{"title":"Exploring the efficacy and constraints of platinum nanoparticles as adjuvant therapy in silicosis management.","authors":"Ge Ban, Yuanjie Chen, Yingbing Liang, Xiaona Wang, Dan Ding, Rui Liu, Jingjing Jia, Ran Zhao, Chenxia Wang, Na Li","doi":"10.1080/10717544.2024.2445257","DOIUrl":"10.1080/10717544.2024.2445257","url":null,"abstract":"Silicosis represents a formidable occupational lung pathology precipitated by the pulmonary assimilation of respirable crystalline silica particulates. This condition engenders a cascade of cellular oxidative stress via the activation of bioavailable silica, culminating in the generation of reactive oxygen species (ROS). Such oxidative mechanisms lead to irrevocable pulmonary impairment. Contemporary scholarly examinations have underscored the substantial antioxidative efficacy of platinum nanoparticles (PtNPs), postulating their utility as an adjunct therapeutic modality in silicosis management. The physicochemical interaction between PtNPs and silica demonstrates a propensity for adsorption, thereby facilitating the amelioration and subsequent pulmonary clearance of silica aggregates. In addition to their detoxifying attributes, PtNPs exhibit pronounced anti-inflammatory and antioxidative activities, which can neutralize ROS and inhibit macrophage-mediated inflammatory processes. Such attributes are instrumental in attenuating inflammatory responses and forestalling subsequent lung tissue damage. This discourse delineates the interplay between ROS and PtNPs, the pathogenesis of silicosis and its progression to pulmonary fibrosis, and critically evaluates the potential adjunct role of PtNPs in the therapeutic landscape of silicosis, alongside a contemplation of the inherent limitations associated with PtNPs application in this context.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2445257"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142970027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ginsenoside compound K-based multifunctional liposomes for the treatment of rheumatoid arthritis. 复方人参皂苷型多功能脂质体治疗类风湿性关节炎。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-02-16 DOI: 10.1080/10717544.2025.2464190

Meng Zhang, Ru Zhang, Chunbo Feng, Xinnan Jiang, Xinchun Xu, Jianxin Wang

{"title":"Ginsenoside compound K-based multifunctional liposomes for the treatment of rheumatoid arthritis.","authors":"Meng Zhang, Ru Zhang, Chunbo Feng, Xinnan Jiang, Xinchun Xu, Jianxin Wang","doi":"10.1080/10717544.2025.2464190","DOIUrl":"10.1080/10717544.2025.2464190","url":null,"abstract":"The clinical treatment of rheumatoid arthritis (RA) with first-line therapeutic drugs is hindered by the poor solubility, low bioavailability, off-target toxicity, and insufficient accumulation in inflamed joints. Liposomes have been shown to mitigate some of these limitations in drug delivery systems. However, the use of cholesterol to stabilize liposomal structures remains controversial due to its potential association with cardiovascular diseases. Here, we developed a novel liposome based on ginsenoside compound K (CK), which not only serves as an effective therapeutic agent for RA but also replaces cholesterol as a membrane stabilizer to address these challenges. Compared with conventional liposomes, ginsenoside CK Liposomes (CK@Lipo) are excellent nanoparticles, with CK stabilizing the liposomal structure and providing targeting functionality toward inflamed joints. When encapsulated with dexamethasone (Dex), CK@Lipo exhibits a synergistic anti-inflammatory effect, slowing the progression of RA. This study provides a theoretical basis for the future development of multifunctional novel ginsenoside CK@Lipo.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2464190"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11834820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomaterial-based drug delivery: evaluating the safety profiles of liposomal Vyxeos. 基于生物材料的给药：评价Vyxeos脂质体的安全性。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-05-02 DOI: 10.1080/10717544.2025.2494781

Zhicheng Liu, Zhuo Fu, Yahui Liu, Yan Jiao

{"title":"Biomaterial-based drug delivery: evaluating the safety profiles of liposomal Vyxeos.","authors":"Zhicheng Liu, Zhuo Fu, Yahui Liu, Yan Jiao","doi":"10.1080/10717544.2025.2494781","DOIUrl":"https://doi.org/10.1080/10717544.2025.2494781","url":null,"abstract":"Vyxeos, a liposomal combination of cytarabine and daunorubicin, has improved survival outcomes for patients with high-risk acute myeloid leukemia (AML). However, its safety profile in real-world settings requires comprehensive evaluation. This study aims to assess the adverse event profiles associated with Vyxeos using data from the U.S. FDA's Adverse Event Reporting System (FAERS). A retrospective analysis of adverse event reports from the FAERS database was conducted for Vyxeos from January 2017 to June 2024. Reports were analyzed to assess patient demographics, system organ classes (SOCs), and preferred terms (PTs). Signal detection analysis was performed using disproportionality metrics, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Multi-Item Gamma Poisson Shrinker (MGPS). A total of 1,036 reports were analyzed. The most frequently reported adverse events were hematologic (37.73%), infectious (28.42%), and cardiac disorders (13.22%). Febrile neutropenia, neutropenic sepsis, and pneumonia fungal were the most commonly reported events, with febrile neutropenia showing a strong association (ROR = 92.18). Males had a higher frequency of infectious events, while females reported more cardiac events. Most adverse events occurred within 30 days of treatment initiation, and 16.92% of reports involved hospitalization, while 18.33% reported death. Vyxeos is associated with significant hematologic, infectious, and cardiac adverse events. Close monitoring, infection prophylaxis, and cardiac assessments are recommended for patients receiving Vyxeos. Further research is needed to validate these findings and explore the mechanisms underlying the observed toxicities.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2494781"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12051568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Reliable high-PAP-1-loaded polymeric micelles for cancer therapy: preparation, characterization, and evaluation of anti-tumor efficacy. 可靠的高载pap -1聚合物胶束用于癌症治疗：制备、表征和抗肿瘤疗效评估。

IF 6.5 2区医学

Drug Delivery Pub Date : 2025-12-01 Epub Date: 2025-04-10 DOI: 10.1080/10717544.2025.2490269

Fang Ye, Qi Li, Longping Huang, Naikai Liao

{"title":"Reliable high-PAP-1-loaded polymeric micelles for cancer therapy: preparation, characterization, and evaluation of anti-tumor efficacy.","authors":"Fang Ye, Qi Li, Longping Huang, Naikai Liao","doi":"10.1080/10717544.2025.2490269","DOIUrl":"https://doi.org/10.1080/10717544.2025.2490269","url":null,"abstract":"The mitochondrial potassium channel Kv1.3 is a critical therapeutic target, as its blockade induces cancer cell apoptosis, highlighting its therapeutic potential. PAP-1, a potent and selective membrane-permeant Kv1.3 inhibitor, faces solubility challenges affecting its bioavailability and antitumor efficacy. To circumvent these challenges, we developed a tumor-targeting drug delivery system by encapsulating PAP-1 within pH-responsive mPEG-PAE polymeric micelles. These self-assembled micelles exhibited high entrapment efficiency (91.35%) and drug loading level (8.30%). As pH decreased, the micelles exhibited a significant increase in particle size and zeta potential, accompanied by a surge in PAP-1 release. Molecular simulations revealed that PAE's tertiary amine protonation affected the self-assembly process, modifying hydrophobicity and resulting in larger, loosely packed particles. Furthermore, compared to free PAP-1 or PAP-1 combined with MDR inhibitors, PAP-1-loaded micelles significantly enhanced cytotoxicity and apoptosis induction in Jurkat and B16F10 cells, through mechanisms involving decreased mitochondrial membrane potential and elevated caspase-3 activity. In vivo, while free PAP-1 failed to reduce tumor size in a B16F10 melanoma mouse model, PAP-1-loaded micelles substantially suppressed tumors, reducing volume by up to 94.26%. Fluorescent-marked micelles effectively accumulated in mouse tumors, confirming their targeting efficiency. This strategy holds promise for significantly improving PAP-1's antitumor efficacy in tumor therapy.","PeriodicalId":11679,"journal":{"name":"Drug Delivery","volume":"32 1","pages":"2490269"},"PeriodicalIF":6.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11986873/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0